Acrivon Therapeutics Highlights AP3 Platform and Pipeline at Cantor Fitzgerald Conference

Acrivon Therapeutics, a biopharmaceutical company with a market capitalization of approximately $90 million, presented its strategic focus on the AP3 Predictive Precision Proteomics platform and its pipeline of therapeutic candidates at the 12th annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026. The company’s financial health reflects a strong balance sheet, with a current ratio of 7.99 and an annual cash burn rate of around $64 million, though it maintains more cash than debt. Shares have risen about 31% over the past six months and declined roughly 13% year-to-date, carrying a stock beta of 1.93. Analyst price targets range from $7 to $19 per share.